{"id":"8727eb8f-30c3-4e56-856c-24dfb40e9978","kind":"institutions","code":"UB-I1304","name":"Xingze Capital","nameBasis":"transliterated","summary":"Xingze Capital is an early-stage investment firm focused on healthcare.","description":"Xingze Capital is an early-stage investment firm focused on healthcare.","country":null,"category":null,"originalName":"杏泽资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:04:26.662Z","englishUpdatedAt":"2026-10-15T20:40:58.142Z","reviewedAt":"2026-10-15T20:40:58.142Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"3956ac0ad7e2c7dd163b34e61512cae95ff66d6a199416f4764163dd3ee97848","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"杏泽资本是专注医疗健康的早期投资机构。","sources":[],"related":[{"id":"611d4988-d4a0-42e4-b9d8-f095e44dcd5b","kind":"news","code":"611d4988-d4a0-42e4-b9d8-f095e44dcd5b","name":"VibrantX raises tens of millions of USD in Series A financing","nameBasis":"translated-title","summary":"","description":"","country":null,"category":null,"originalName":"信华生物完成数千万美元A轮融资","eventDate":"2025-08-25T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-13T17:03:30.815Z","englishUpdatedAt":"2026-10-15T17:19:59.568Z","reviewedAt":"2026-10-15T17:19:59.568Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"c3036d6160884831e8936e56f9524da9dc482fad7c45cfc0fe14367db0c1ed0a","companyId":"d43b8419-232a-4bf4-bde8-8866697282d6","foundedYear":null,"logoUrl":null,"path":"/news/611d4988-d4a0-42e4-b9d8-f095e44dcd5b"},{"id":"a5d162ba-fab7-47ee-ab19-afb2e114ba51","kind":"news","code":"a5d162ba-fab7-47ee-ab19-afb2e114ba51","name":"Zhiran Medical Raises RMB 600M in Equity Investment","nameBasis":"translated-title","summary":"On September 22, 2026, Beijing-based Zhiran Medical, a next-generation flexible brain-computer interface platform developer, raised RMB 600 million from over ten investors including Shunxi Fund, Sequoia China, Junlian Capital, Shunwei Capital, Meituan Longzhu and CAS Star. It was founded by Dr. Song Qi.","description":"","country":null,"category":null,"originalName":"智冉医疗完成6亿元股权投资","eventDate":"2026-09-22T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-14T11:44:26.930Z","englishUpdatedAt":"2026-10-15T16:49:02.926Z","reviewedAt":"2026-10-15T16:49:02.926Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"20f67d25ca26c8e11d0aa3e41f47b9d223978732510f400ead359c6f99f688e3","companyId":"1ef56388-71d4-4402-bbd4-73a3657f5fb4","foundedYear":null,"logoUrl":null,"path":"/news/a5d162ba-fab7-47ee-ab19-afb2e114ba51"},{"id":"55168274-31ef-440b-a1f2-e58fc5f91ed0","kind":"news","code":"55168274-31ef-440b-a1f2-e58fc5f91ed0","name":"Zhiran Medical raises RMB 300 million in Series A+ financing","nameBasis":"translated-title","summary":"On 2026-02-11, according to Xiniu Data, Zhiran Medical completed Series A+ financing, raising RMB 300 million. Investors were Yuansheng Venture Capital, Junlian Capital, Hongshan China, Xingze Capital and others.","description":"","country":null,"category":null,"originalName":"智冉医疗完成A+轮融资，金额3亿人民币","eventDate":"2026-02-11T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-16T19:46:29.324Z","englishUpdatedAt":"2026-10-18T08:52:13.862Z","reviewedAt":"2026-10-18T08:52:13.862Z","snapshotAt":"2026-10-18T08:51:49.337Z","sourceHash":"c97757e0251430fd7f15e8bd58e5ff9cac832a3069db603d9d6bc989d9bf75e2","companyId":"1ef56388-71d4-4402-bbd4-73a3657f5fb4","foundedYear":null,"logoUrl":null,"path":"/news/55168274-31ef-440b-a1f2-e58fc5f91ed0"},{"id":"a3799465-6142-4482-a199-e95e03442e40","kind":"news","code":"a3799465-6142-4482-a199-e95e03442e40","name":"iRegene raises RMB 210 million in Series C financing","nameBasis":"translated-title","summary":"On 2026-04-27, according to Xiniu Data, iRegene completed Series C financing, raising RMB 210 million. Investors were co-lead investor Nantongheyuanyihao Venture Capital Partnership (Limited Partnership), co-lead investor Xingze Capital. The company is a developer of chemically induced cell therapy drugs.","description":"","country":null,"category":null,"originalName":"睿健医药完成C轮融资，金额2.10亿人民币","eventDate":"2026-04-27T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-15T17:18:22.746Z","englishUpdatedAt":"2026-10-15T19:44:30.494Z","reviewedAt":"2026-10-15T19:44:30.494Z","snapshotAt":"2026-10-15T18:31:34.288Z","sourceHash":"12ad14aa25ef752ac18e386497b821bf4edffd029f09cf9175854d7f56fe563a","companyId":"c6f40f74-5248-4720-8404-fd1e03022e90","foundedYear":null,"logoUrl":null,"path":"/news/a3799465-6142-4482-a199-e95e03442e40"}],"path":"/institutions/xingze-capital","displayName":"杏泽资本","displayNameLang":"zh","structured":{"city":null,"country":"China (mainland)","location":null,"role":null,"category":null,"company":null},"definition":"杏泽资本 is a venture capital investor based in China (mainland) with 4 recorded investments in 3 companies.","summaryBasis":"translated","thin":false,"canonical":"https://uniquebase.ai/institutions/xingze-capital"}